A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet

Stollenwerk, B., Iannazzo, S., Akehurst, R., Adena, M., Briggs, A. , Dehmel, B., Parfrey, P. and Belozeroff, V. (2018) A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. PharmacoEconomics, 36(5), pp. 603-612. (doi: 10.1007/s40273-017-0605-2) (PMID:29392552)

157205.pdf - Accepted Version



Introduction: Etelcalcetide is a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in haemodialysis patients. The clinical efficacy and safety of etelcalcetide (in addition to phosphate binders and vitamin D and/or analogues [PB/VD]) was evaluated in three phase III studies, including two placebo-controlled trials and a head-to-head study versus the oral calcimimetic cinacalcet. Objective: The objective of this study was to develop a decision-analytic model for economic evaluation of etelcalcetide compared with cinacalcet. Methods: We developed a life-time Markov model including potential treatment effects on mortality, cardiovascular events, fractures, and subjects’ persistence. Long-term efficacy of etelcalcetide was extrapolated from the reduction in parathyroid hormone (PTH) in the phase III trials and the available data from the outcomes study in cinacalcet (EVOLVE trial). Etelcalcetide was compared with cinacalcet, both in addition to PB/VD. We applied unit costs averaged from five European countries and a range of potential etelcalcetide pricing options assuming parity price to weekly use of cinacalcet and varying it by a 15 or 30% increase. Results: Compared with cinacalcet, the incremental cost-effectiveness ratio of etelcalcetide was €1,355 per QALY, €24,521 per QALY, and €47,687 per QALY for the three prices explored. The results were robust across the probabilistic and deterministic sensitivity analyses. Conclusions: Our modelling approach enabled cost-utility assessment of the novel therapy for SHPT based on the observed and extrapolated data. This model can be used for local adaptations in the context of reimbursement assessment.

Item Type:Articles
Additional Information:Financial support for this study was provided by Amgen.
Glasgow Author(s) Enlighten ID:Briggs, Professor Andrew
Authors: Stollenwerk, B., Iannazzo, S., Akehurst, R., Adena, M., Briggs, A., Dehmel, B., Parfrey, P., and Belozeroff, V.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:PharmacoEconomics
ISSN (Online):1179-2027
Published Online:02 February 2018
Copyright Holders:Copyright © 2018 Springer International Publishing AG, part of Springer Nature
First Published:First published in PharmacoEconomics 36(5): 603-612
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record